Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 19;16(4):617.
doi: 10.3390/ph16040617.

Patient-Centric Design of Topical Dermatological Medicines

Rita Oliveira  1   2   3 , Isabel F Almeida  2   3
Affiliations
Review

Patient-Centric Design of Topical Dermatological Medicines

Rita Oliveira et al. Pharmaceuticals (Basel). .

Abstract

Topical treatments are essential approaches to skin diseases but are associated with poor adherence. Topical vehicles have the primary purpose of ensuring drug effectiveness (by modulating drug stability and delivery, as well as skin properties) but have a marked impact on treatment outcomes as they influence patient satisfaction and, consequently, adherence to topical treatments. There is also a wide variety of vehicles available for topical formulations, which can complicate the decisions of clinicians regarding the most appropriate treatments for specific skin disorders. One of the possible strategies to improve topical-treatment adherence is the implementation of patient-centric drug-product design. In this process, the patient's needs (e.g., those related to motor impairment), the needs associated with the disease (according to the skin lesions' characteristics), and the patient's preferences are taken into consideration and translated into a target product profile (TPP). Herein, an overview of topical vehicles and their properties is presented, along with a discussion of the patient-centric design of topical dermatological medicines and the proposal of TPPs for some of the most common skin diseases.

Keywords: adherence; drug-product design; patient-centric; topical medicines; vehicles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patient-centric drug-product-design stepwise approach.
Figure 2
Figure 2
TPP for formulations for eczema-lesion treatment and most suitable vehicles/bases.
Figure 3
Figure 3
TPP for formulations for psoriasis treatment and most suitable vehicles/bases.
Figure 4
Figure 4
TPP for formulations for rosacea treatment and most suitable vehicles/bases.
Figure 5
Figure 5
TPP for formulations for treatment of seborrheic dermatitis and most suitable vehicles/bases.
Figure 6
Figure 6
TPP for formulations for acne treatment and most suitable vehicles/bases.
Figure 7
Figure 7
TPP for formulations for treatment of atopic dermatitis and most suitable vehicles/bases.
Figure 8
Figure 8
TPP for formulations for treatment of pigmentation disorders and most suitable vehicles/bases.
See this image and copyright information in PMC

References

    1. Ana Teixeira M.T., Almeida V., Almeida I.F. Adherence to Topical Treatment in Psoriasis. In: Costa E., Giardini A., Monaco A., editors. Adherence to Medical Plans for Active and Healthy Ageing. Nova Science Publishers, Incorporated; New York, NY, USA: 2017.
    1. Augustin M., Holland B., Dartsch D., Langenbruch A., Radtke M.A. Adherence in the treatment of psoriasis: A systematic review. Dermatology. 2011;222:363–374. doi: 10.1159/000329026. - DOI - PubMed
    1. Miyachi Y., Hayashi N., Furukawa F., Akamatsu H., Matsunaga K., Watanabe S., Kawashima M. Acne management in Japan: Study of patient adherence. Dermatology. 2011;223:174–181. doi: 10.1159/000332847. - DOI - PubMed
    1. Snyder A., Farhangian M., Feldman S.R. A review of patient adherence to topical therapies for treatment of atopic dermatitis. Cutis. 2015;96:397–401. - PubMed
    1. Teixeira A., Oliveira C., Teixeira M., Rita Gaio A., Lobo J.M.S., de Almeida I.F.M., Almeida V. Development and Validation of a Novel Questionnaire for Adherence with Topical Treatments in Psoriasis (QATOP) Am. J. Clin. Dermatol. 2017;18:571–581. doi: 10.1007/s40257-017-0272-2. - DOI - PubMed

LinkOut - more resources